Literature DB >> 10235157

Rising incidence of renal cell cancer in the United States.

W H Chow1, S S Devesa, J L Warren, J F Fraumeni.   

Abstract

CONTEXT: Clinical surveys have revealed that incidental detection of renal cell carcinoma is rising because of increased use of imaging procedures.
OBJECTIVE: To examine incidence, mortality, and survival trends of renal cell and renal pelvis cancers by age, sex, race, and tumor stage at diagnosis.
DESIGN: Calculation of age-adjusted incidence and mortality rates, along with 5-year relative survival rates, using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. SETTING AND PARTICIPANTS: Patients diagnosed as having kidney cancer from 1975 through 1995 in the 9 geographic areas covered by tumor registries in the SEER program, which represent about 10% of the US population. MAIN OUTCOME MEASURES: Incidence, mortality, and 5-year relative survival rates by time periods.
RESULTS: The age-adjusted incidence rates for renal cell carcinoma between 1975 and 1995 for white men, white women, black men, and black women were 9.6, 4.4, 11.1, and 4.9 per 100000 person-years, respectively. The corresponding rates for renal pelvis cancer were 1.5, 0.7, 0.8, and 0.5 per 100000 person-years. Renal cell cancer incidence rates increased steadily between 1975 and 1995, by 2.3% annually among white men, 3.1 % among white women, 3.9% among black men, and 4.3% among black women. Increases were greatest for localized tumors but were also seen for more advanced and unstaged tumors. In contrast, the incidence rates for renal pelvis cancer declined among white men and remained stable among white women and blacks. Although 5-year relative survival rates for patients with renal cell cancer improved among whites but not among blacks, kidney cancer mortality rates increased in all race and sex groups.
CONCLUSIONS: Increasing detection of presymptomatic tumors by imaging procedures, such as ultrasonography, computed tomography, and magnetic resonance imaging, does not fully explain the upward incidence trends of renal cell carcinoma. Other factors may be contributing to the rapidly increasing incidence of renal cell cancer in the United States, particularly among blacks.

Entities:  

Mesh:

Year:  1999        PMID: 10235157     DOI: 10.1001/jama.281.17.1628

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  392 in total

1.  Vitamin D receptor FokI and BsmI gene polymorphism and its association with grade and stage of renal cell carcinoma in North Indian population.

Authors:  Wani Arjumand; Shiekh Tanveer Ahmad; Amlesh Seth; Ashish Kumar Saini; Sarwat Sultana
Journal:  Tumour Biol       Date:  2011-09-20

2.  Thermal protection during percutaneous thermal ablation of renal cell carcinoma.

Authors:  Anthony W Kam; Peter J Littrup; McClellan M Walther; Julia Hvizda; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2004-07       Impact factor: 3.464

Review 3.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

4.  Active surveillance as the preferred management option for small renal masses.

Authors:  Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

5.  Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.

Authors:  Won K Han; Anwar Alinani; Chin-Lee Wu; Dror Michaelson; Massimo Loda; Francis J McGovern; Ravi Thadhani; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2005-03-02       Impact factor: 10.121

6.  Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients.

Authors:  Yuichi Uwai; Satohiro Masuda; Maki Goto; Hideyuki Motohashi; Hideyuki Saito; Masahiro Okuda; Eijirou Nakamura; Noriyuki Ito; Osamu Ogawa; Ken-Ichi Inui
Journal:  J Hum Genet       Date:  2003-12-18       Impact factor: 3.172

7.  Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma.

Authors:  Christopher S Saigal; Christopher M Deibert; Julie Lai; Matthias Schonlau
Journal:  Urol Oncol       Date:  2008-12-12       Impact factor: 3.498

8.  Low C24-OH and C22-OH sulfatides in human renal cell carcinoma.

Authors:  Il Chan Kim; Geul Bang; Jeong Hwa Lee; Kwang Pyo Kim; Young Hwan Kim; Hark Kyun Kim; Jinsoo Chung
Journal:  J Mass Spectrom       Date:  2014-05       Impact factor: 1.982

9.  Molecular targeted therapies of renal cell carcinoma considering life stage of the patient: Two case reports.

Authors:  Hisashi Takeuchi; Naoto Tokuyama; Isao Kuroda; Teiichiro Aoyagi
Journal:  Exp Ther Med       Date:  2018-02-20       Impact factor: 2.447

10.  Inhibition of PKCα reduces the ability of migration of kidney cancer cells but has no impact on cell apoptosis.

Authors:  Bo Zhan; Chuize Kong; Zhe Zhang; Xiao Dong; Naiwen Zhang
Journal:  Exp Ther Med       Date:  2017-03-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.